Collaboration aims to uncover biomarkers for prostate cancer

04/23/2013 | GenomeWeb Daily News (free registration)

The Ontario Institute for Cancer Research has agreed to work with Johnson & Johnson unit Janssen on clinical trials that aim to develop new biomarkers for detecting hormone-resistant prostate cancer and predicting therapeutic response. The project will leverage OICR's background in molecular imaging, genomics and circulating tumor cells. As part of the project, researchers will test new imaging agents in tumor evaluation and treatment response assessment.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ